DPT News Releases

October 29, 2014 – DPT Enhances Capabilities with New High-Speed Filling Center at its San Antonio Center of Excellence

DPT Laboratories, a Contract Development and Manufacturing Organization (CDMO) specializing in semi-solid and liquid dosage forms, announces the implementation of a high-speed bottle filling center at its San Antonio location.

- Download (PDF, 120 KB)

September 4, 2014 – DPT Laboratories Acquires Meda Pharmaceuticals’ Lakewood, New Jersey, Location

DPT Laboratories, a contract development and manufacturing organization (CDMO) with a specialized focus on semi-solid and liquid dosage forms, announces the acquisition of Meda Pharmaceuticals’ Lakewood, New Jersey, facilities.

- Download (PDF, 26 KB)

October 16, 2013 – DPT Laboratories, Confab Announce Integration.

Pharmaceutical contract development and manufacturing organizations (CDMOs) DPT Laboratories, based in San Antonio, Texas, and Confab, based in Saint-Hubert, Quebec, today announced the integration of the organizations under the leadership of Paul Johnson, Group President and COO.

- Download (PDF, 39 KB)

March 19, 2013 – DPT Laboratories Receives Close-Out Letter from U.S. FDA

DPT Laboratories, a contract development and manufacturing organization (CDMO), received notification from the U.S. Food and Drug Administration (FDA) on February 19, 2013 that signaled the completion of their evaluation of DPT’s corrective actions taken at its Lakewood, NJ facility in response to the warning letter received on August 27, 2012.

- Download (PDF, 16 KB)

October 31, 2012 – East Coast CMOs relatively unscathed by superstorm Sandy

Superstorm Sandy leaves east cost CMOs relatively unscathed; DPT reports no facility damage in Lakewood.

- Read More at Outsourcing Pharma

October 17, 2012 – Challenges in Topical Drug Manufacturing – Tools and strategies for optimizing the manufacturing process

DPT scientist explains how an ideal topical formulation can be produced using a simple, flexible process, however most topical formulations developed today are more complex and therefore require tightly controlled processing parameters.

- Read More at Pharm Tech

September 6, 2012 – Conversation about acquiring DPT, the future of CDMOs and more

Contract Pharma interviewed Pierre Frechette, president and chief executive officer of Renaissance Pharma to discuss the process of buying DPT, his group’s philosophy regarding acquisitions and operations, and DPT’s synergies with another recent acquisition.

- Read More at Contract Pharma

September 5, 2012 – Executive Interview with Paul Johnson

Drug Development & Delivery interviewed Paul Johnson, DPT Group President and Chief Operating Officer, to discuss the consistent growth and success of DPT, its expansion in the sterile arena, and plans for the future.

- Read More at Drug Development & Delivery

July 5, 2012 – Renaissance Acquisition Holdings, LLC Acquires DPT Laboratories

Renaissance Acquisition Holdings, LLC (“Renaissance”), a portfolio company of RoundTable Healthcare Partners (“RoundTable”), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has acquired DPT Laboratories, a contract development and manufacturing organization (CDMO).

- Download (PDF, 31 KB)

May 23, 2012 – DPT Names Jeanette Riedle Senior Director of Continuous Improvement

DPT Laboratories, a contract development and manufacturing organization (CDMO), announced today that Jeanette Riedle has been named Senior Director of Continuous Improvement.

- Download (PDF, 17 KB)

February 20, 2012 – DPT Names Kuljit Bhatia Vice President of Research and Development

DPT announced today that Kuljit S. Bhatia, Ph.D., has been named Vice President of R&D. Bhatia, who has more than 15 years of pharmaceutical experience in drug product development, previously was VP of R&D Technical Operations at Fougera Pharmaceuticals (formerly Nycomed) in Long Island, NY. Prior to joining Fougera, he held senior R&D positions at Medicis Pharmaceuticals and Mylan Technologies Inc.

- Download (PDF, 30 KB)

November 28, 2011 – DPT Scientist to be Featured in Webcast on Topical Drug Sector

Michael Lowenborg, R&D manager of formulation and process development at DPT, will be featured in a Dec. 7 webcast offering insights from leading pharmaceutical industry experts on “Optimizing Topical Drug Formulations and Manufacturing.” The 60-minute webcast, at 2 p.m. EST, is presented by Pharmaceutical Technology magazine, which notes that the topic is increasingly important to pharmaceutical companies seeking innovative ways to improve drug delivery and patient compliance.

- Download (PDF, 19 KB)

October 12, 2011 – DPT Reinforces Commitment to Semi-solids and Liquids Market with Continued Investment in Manufacturing Facilities

DPT announced continued investments in its manufacturing facilities that further cement its position as the industry leader for semi-solids and liquids. Since completing $45 million in capacity expansion and equipment upgrades for its San Antonio, TX and Lakewood, NJ facilities in mid-2010, DPT plans to invest another $14 million in the facilities.

- Download (PDF, 38 KB)

July 27, 2011 – DPT Announces Business Development Promotion and Team Structure Change

DPT announced that Lynn Allen has been promoted to Dir., Business Development – Western U.S. Region & Europe and that the company has restructured the Business Development team.

- Download (PDF, 22 KB)

May 18, 2011 – DPT and Proveris Scientific Host Joint Webinar on Obtaining the Right Data for Inhalation Products

DPT will host a webinar with Proveris on June 15 at 11 a.m. CST to explain how pharmaceutical manufacturers ensure the right bioavailability and bioequivalence data is obtained for inhalation products in development.

- Download (PDF, 44 KB)

March 25, 2011 – DPT Hosts University of Texas Doctoral Students

DPT welcomed more than 20 students from the AAPS student chapter at the University of Texas College of Pharmacy Pharmaceutics Department to tour its San Antonio facilities on March 25. The tour allowed students to see first-hand the extent of our operations beginning with pharmaceutical development activities through commercial manufacturing.

- Download (PDF, 288 KB)

For all media inquires please call 210-396-5008 or click here.